ConductScience.org, home

Trial · NCT03989947

Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryEvaluate the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]"Through study completion, an average of 5 years"Number of study participants with treatment-emergent adverse events or serious adverse events
PrimaryEvaluate change in height/length z-score in children with ACH treated with BMN 111"Through study completion, an average of 5 years"
SecondaryEvaluate the change from baseline of mean annualized growth velocity (AGV)"Through study completion, an average of 5 years"
SecondaryCharacterize maximum concentration (Cmax) of BMN 111 in plasma"Through study completion, an average of 5 years"
SecondaryCharacterize the area under the plasma concentration time-curve from time 0 to infinity (AUC0-∞)"Through study completion, an average of 5 years"
SecondaryCharacterize the elimination half-life of BMN 111 (t½)"Through study completion, an average of 5 years"
SecondaryCharacterize the apparent clearance of drug"Through study completion, an average of 5 years"
SecondaryCharacterize the apparent volume of distribution based upon the terminal phase (Vz/F)"Through study completion, an average of 5 years"
SecondaryCharacterize the amount of time BMN 111 is present at maximum concentration (Tmax)"Through study completion, an average of 5 years"
SecondaryEvaluate the change from baseline on body proportion ratios of the extremities"Through study completion, an average of 5 years"
SecondaryEffect of BMN 111 on bone morphology and quality by XRay"Through study completion, an average of 5 years"
SecondaryThe effect of BMN 111 on bone morphology/quality will be assessed by measuring bone mineral density via Dual X-ray Absorptiometry"Through study completion, an average of 5 years"
SecondaryPotential Changes in health-related quality of life as measured by the quality of life in Short- statured youth"Through study completion, an average of 5 years"
Evaluate the long-term effect of BMN 111 on health-related quality of life, developmental status and functional independence, using age-specific QoL and functional independence questionnaires (Bayley-III, WeeFIM, ITQOL, QoLISSY, PedsQL, Child Behavior Checklist 1.5-5 \[CBCL 1.5-5\], Child Behavior Checklist 6-18 \[CBCL 6-18\]).
SecondaryBMN 111 activity will be assessed by measuring bone and collagen metabolism"Through study completion, an average of 5 years"
SecondaryDescribe the incidence of surgical and medical interventions related to achondroplasia"Through study completion, an average of 5 years"
SecondaryAssess effect on sleep disordered breathing by polysomnography in patients up to 5 years old."Through study completion, an average of 1 year"
SecondaryEvaluate the effect of BMN 111 on skull and brain morphology, including foramen magnum, ventricular and brain parenchymal dimensions by MRI in patients up to 3 years old."Through study completion, an average of 1 year"

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03989947/registered